The Acheivement’s of Proove Bio

News and Media

A medical test that aims to wean America off painkillers

The headlines about Prince's reported painkiller addiction have captured the nation's attention, but the stats on America's opioid crisis show that it's in no way surprising. Opioid addiction claimed 28,000 deaths in 2014, half from painkiller prescriptions, the...

December 7, 2016 – Proove Release: Proove Launches First Precision Medicine Test for TMJ Disorder

by | February 12, 2018 | In the News | 0 Comments

Proove Launches the Only Commercially Available Genetic Analysis Offering Personalized Medical Treatment Recommendations for TMD Sufferers and Insights Into Contributing Causes of Orofacial Pain IRVINE, CA--(Marketwired - Dec 7, 2016) - Proove Biosciences, Inc., the...
Read More

April 25, 2017 – Proove Release: Milestone of the World’s Largest Biobank and Big Data Set in Chronic Pain –

by | February 12, 2018 | Press Releases | 0 Comments

Proove® Announces Huge Milestone for its Proove Nexus™ Big Data Platform Commemorating National DNA Day IRVINE, Calif., April 25, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces that its Proove Nexus™ platform is the World's Largest DNA Pain Biobank and Big...
Read More

October 23, 2015 – Proove Release: Proove Partners with USC to Conduct Research

by | February 12, 2018 | Press Releases | 0 Comments

Proove Biosciences, a commercial and research leader in personalized medicine, is excited to announce their partnership with the Keck Medicine of the University of Southern California(USC) Pain Center to study the genetics of chronic pain. The T.R.O.J.A.N. Study...
Read More

April 19, 2017 – Proove Release: First Published Study of Precision Medicine to Predict Opioid Abuse

by | February 12, 2018 | Press Releases | 0 Comments

Results Published in the Journal Pharmacogenomics and Personalized Medicine Shows Proove Opioid Risk® Accurately Identifies Prescription Opioid Abuse Risk IRVINE, Calif., April 19, 2017 /PRNewswire/ -- As a Bronze Sponsor of the National Rx Drug Abuse and Heroin...
Read More

August 2, 2017 | Proove Release: 7 th Published Peer-Reviewed Study in Last 7 Months Supports Proove Technology to Predict Opioid Abuse

by | February 12, 2018 | Press Releases | 0 Comments

New Peer-Reviewed Prospective Study Shows that Proove Opioid Risk® Profile Results in Better Pain Management Decisions Providing a 50% Reduction in Pain IRVINE, Calif., Aug. 2, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces yet another new...
Read More

April 15, 2014 – Proove Release: Proove Wins Award from American Society of Interventional Pain Physicians for Its Research

by | February 12, 2018 | Press Releases | 0 Comments

Proove Biosciences' Presented Research on the Predictive Risk of Workers Compensation Claims Extending Beyond One Year Irvine, CA (PRWEB) April 15, 2014 Proove Biosciences, the leader in Personalized Pain Medicine testing services, exhibited and presented three...
Read More

May 10, 2017 – Proove Release: Proove Publishes Another Study Validating 97% Accuracy of Opioid Risk Technology

by | February 12, 2018 | Press Releases | 0 Comments

Results Published in the Journal of Addiction Research and Therapy Shows Nearly 97% Accuracy in Identifying Patients At-Risk of Prescription Opioid Abuse IRVINE, Calif., May 10, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces a new study validating the...
Read More

May 31, 2017 – Proove Release: Preliminary Results from Large Clinical Utility Study of Over 27,000 Patients Shows 90% of Patients Experience Significant Pain Reduction From Decisions Made with Proove Technology

by | February 12, 2018 | Press Releases | 0 Comments

Preliminary Results of 27,659 patients from MOSAIC Trial Demonstrate that Proove® Technology Leads to Better Patient Outcomes IRVINE, Calif., May 31, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces preliminary results at the close of a large patient-centered...
Read More

April 7, 2015 – Proove Release: Proove Launches Opioid Response Test

by | February 12, 2018 | Press Releases | 0 Comments

(PRWEB) APRIL 07, 2015 Proove Biosciences a commercial and research leader in Personalized Medicine, is excited to announce the launch of Proove Opioid Response - the world’s first clinical laboratory test to predict responders to opioid pain medications. Building on...
Read More

April 23, 2015 – Proove Release: Proove Biosciences Launches World's First Test To Predict Responders To Commonly Prescribed Non-Opioid Pain Medications

by | February 12, 2018 | In the News | 0 Comments

The new Proove Non-Opioid Pain Medication Response profile evaluates genetic factors to predict a patient’s response to non opioids before prescribing Irvine, CA (PRWEB) - Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited to...
Read More

Video’s

A medical test that aims to wean America off painkillers

The headlines about Prince's reported painkiller addiction have captured the nation's attention, but the stats on America's opioid crisis show that it's in no way surprising. Opioid addiction claimed 28,000 deaths in 2014, half from painkiller prescriptions, the...

Get Instant Access to Updates to The Truth about Proove Bio